Cheri Walker

Brickbio, Inc. operates as a bioconjugation platform for site-specific, site-selective modification of antibodies and other proteins. The company was founded by John Boyce and James Italia and is headquartered in Woburn, MA.

Firefly BioWorks, Inc. develops an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed assays on standard laboratory instrumentation. It offers Multiplex Cellular miRNA and Multiplex Circulating miRNA Assays that use Firefly particle technology to enable simultaneous analysis of 68 miRNAs per well; and vacuum manifold for 96 well filter plates. The company was founded by Davide M. Marini and Daniel C. Pregibon in 2009 and is headquartered in Cambridge, MA.

Firefly BioWorks, Inc. develops an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed assays on standard laboratory instrumentation. It offers Multiplex Cellular miRNA and Multiplex Circulating miRNA Assays that use Firefly particle technology to enable simultaneous analysis of 68 miRNAs per well; and vacuum manifold for 96 well filter plates. The company was founded by Davide M. Marini and Daniel C. Pregibon in 2009 and is headquartered in Cambridge, MA.

Brickbio, Inc. operates as a bioconjugation platform for site-specific, site-selective modification of antibodies and other proteins. The company was founded by John Boyce and James Italia and is headquartered in Woburn, MA.

Brickbio, Inc. operates as a bioconjugation platform for site-specific, site-selective modification of antibodies and other proteins. The company was founded by John Boyce and James Italia and is headquartered in Woburn, MA.